Cara Therapeutics Sees Unusually Large Options Volume (CARA)

Share on StockTwits

Cara Therapeutics Inc (NASDAQ:CARA) saw some unusual options trading activity on Thursday. Investors bought 5,060 put options on the company. This is an increase of 830% compared to the average volume of 544 put options.

A number of equities research analysts have commented on CARA shares. HC Wainwright reissued a “buy” rating and issued a $22.00 price objective on shares of Cara Therapeutics in a research report on Monday, March 12th. BidaskClub downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, March 20th. Zacks Investment Research raised shares of Cara Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, March 21st. Seaport Global Securities reissued a “buy” rating on shares of Cara Therapeutics in a research report on Friday, March 16th. Finally, ValuEngine downgraded shares of Cara Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 22nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. Cara Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $24.63.

Shares of Cara Therapeutics stock opened at $19.27 on Friday. Cara Therapeutics has a 12-month low of $11.11 and a 12-month high of $27.35. The firm has a market capitalization of $590.56 million, a PE ratio of -10.36 and a beta of 3.03.

Cara Therapeutics (NASDAQ:CARA) last issued its earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.51) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.04). sell-side analysts expect that Cara Therapeutics will post -2.17 earnings per share for the current year.

In other Cara Therapeutics news, SVP Frederique Ph.D. Menzaghi sold 3,000 shares of the stock in a transaction that occurred on Friday, June 1st. The shares were sold at an average price of $15.49, for a total value of $46,470.00. Following the sale, the senior vice president now directly owns 107,000 shares of the company’s stock, valued at approximately $1,657,430. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Corporate insiders own 6.70% of the company’s stock.

Several institutional investors have recently modified their holdings of CARA. MANA Advisors LLC acquired a new position in shares of Cara Therapeutics in the 4th quarter valued at $125,000. MetLife Investment Advisors LLC acquired a new position in shares of Cara Therapeutics in the 4th quarter valued at $140,000. DekaBank Deutsche Girozentrale acquired a new position in shares of Cara Therapeutics in the 1st quarter valued at $164,000. Paloma Partners Management Co acquired a new position in shares of Cara Therapeutics in the 4th quarter valued at $167,000. Finally, Raymond James & Associates acquired a new position in shares of Cara Therapeutics in the 4th quarter valued at $199,000. Institutional investors and hedge funds own 54.42% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply